Every 8-K that Ainos, Inc. Warrants (AIMDW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AIMDW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIMDW filings page.
Ainos, Inc. reported second-quarter 2026 results, highlighting ongoing commercialization of its AI Nose Smell AI platform while remaining deeply loss-making. Revenue for the quarter ended June 30, 2026 was $152, down from $4,663 a year earlier; six-month revenue was $313 versus $110,870 in 2025.
The company recorded a Q2 2026 net loss of $(4,594,731) compared with $(4,084,990) in Q2 2025, and a six-month net loss of $(7,054,531) versus $(7,371,012). Basic and diluted net loss per share was $(0.62) for the quarter and $(1.05) year-to-date. Cash and cash equivalents increased to $1,422,912 at June 30, 2026 from $417,353 at December 31, 2025.
Balance sheet leverage rose, with current liabilities of $16,277,500 including $11,000,000 of current convertible notes and a $2,812,940 loan payable. Total stockholders’ equity declined to $3,283,985, driven by an accumulated deficit of $(74,574,859). Management emphasized expanding AI Nose deployments, an initial $2.1 million backend semiconductor arrangement, and datasets totaling approximately 613 million industrial smell records to support its Smell AI platform.
Ainos, Inc., a Texas-based company listed on Nasdaq under AIMD and AIMDW, changed its independent registered public accounting firm. On July 9, 2026, the company dismissed YCM CPA INC. following expiration of its engagement and, on the same day, the audit committee engaged DLEE Accountancy, Inc. as the new independent registered public accounting firm.
The company states it had no disagreements with YCM on accounting principles, financial statement disclosure, or auditing scope or procedures, and reports no “reportable events” as defined in Item 304(a)(1)(v) of Regulation S‑K. Ainos indicates it did not consult DLEE on potential audit opinions or accounting issues before the engagement. YCM has been asked to provide a letter to the SEC regarding its agreement with these statements.
Ainos, Inc. entered into a General Agreement for Omnibus Credit Lines with CTBC Bank Co., Ltd., providing a short-term unsecured credit facility of NT$62,000,000 (approximately US$1,937,800). Outstanding borrowings bear interest at 2.5% per annum. The facility has a three-month term and matures on September 30, 2026. It is unsecured and includes customary events of default, giving Ainos additional near-term funding flexibility.
Ainos, Inc. reported first quarter 2026 results showing minimal revenue and a narrower loss as it advances its AI Nose commercialization strategy. Revenue for the quarter was $161, compared with $106,207 a year earlier, reflecting the shift toward infrastructure-focused AI Nose deployments still in early stages.
The company reported a net loss of $2.46 million, improving from a $3.29 million loss in the prior-year quarter, as operating expenses declined about 30% year-over-year to approximately $2.28 million. Cash and cash equivalents rose to $2.84 million from $0.42 million, supported by a previously announced NT$90 million (approximately $2.8 million) financing, while total liabilities increased to $16.39 million and stockholders’ equity decreased to $5.69 million.
Operationally, Ainos continued deploying AI Nose under a roughly three-year $2.1 million commercial arrangement in backend semiconductor manufacturing, initiated pilots in front-end semiconductor environments, expanded healthcare infrastructure pilots, and further developed its Smell ID datasets and Smell Language Model to support long-term Smell AI platform commercialization.
Ainos, Inc. reported full-year 2025 results and highlighted early commercialization of its AI Nose platform. Revenue reached $124,157, up about 499% from 2024, with gross margin turning positive at roughly 82.9% after a prior-year gross loss.
Despite this top-line growth, Ainos posted a net loss of about $14.8 million, similar to 2024, as operating expenses were roughly $14.1 million. Cash and cash equivalents fell to about $417,353 versus $3.9 million a year earlier. After year-end the company raised NTD 90 million (approximately $2.82 million) to support operations and AI Nose deployment.
For 2026, Ainos is rolling out AI Nose in semiconductor environments, including around 200 systems for front-end wafer fabs and about 1,400 systems under a three-year $2.1 million deployment in semiconductor packaging and testing, with a potential roadmap to scale substantially if validations succeed.
Ainos, Inc. filed an 8-K to report an update to its at-the-market stock offering program with H.C. Wainwright & Co., LLC as placement agent. The company previously established an agreement on May 31, 2024 to sell common stock with an aggregate offering price of up to $1,353,197, which was increased by a July 11, 2024 prospectus supplement to $1,840,350. Ainos has already sold common shares with an aggregate sales price of approximately $1,840,337 under this program. On September 5, 2025, Ainos filed a new prospectus supplement for an additional $874,496 of common stock under the same at-the-market agreement.
Ainos, Inc. reported that it furnished its financial results for the quarter ended June 30, 2025 via a Current Report on Form 8-K dated August 13, 2025. The filing states a press release announcing those results is furnished as Exhibit 99.1 and that a Cover Page Interactive Data File is included as Exhibit 104. The report notes these materials are being furnished and are not deemed "filed" for purposes of Section 18 of the Exchange Act.
The 8-K identifies the company as a Texas corporation with principal offices in San Diego and lists its common stock (AIMD) and warrants (AIMDW) as Nasdaq-listed securities. The report is signed by Chun-Hsien Tsai, Chief Executive Officer. No financial amounts or results are included directly in the text of this Form 8-K.
Form 8-K – Item 8.01 Other Events
On 6-Aug-2025, Ainos, Inc. (Nasdaq: AIMD; AIMDW) reported that it has secured a US$2.1 million order from ASE Technology Holding Co., Ltd. to deploy the company’s AI Nose sensing platform in a semiconductor manufacturing environment. The related press release is provided as Exhibit 99.1.
The filing contains no revisions to previously issued financial statements, no earnings guidance, and no additional contractual terms beyond the order’s value and intended use. Other than standard cover information, Items 8.01 and 9.01 are the only sections with substantive disclosure.
Ainos announced a strategic partnership with Kenmec Mechanical Engineering through an 8-K filing dated June 24, 2025. The company, listed on the Nasdaq Stock Market under symbols AIMD (common stock) and AIMDW (warrants), made this material disclosure in accordance with SEC regulations.
Key details from the filing:
- The partnership agreement is legally binding, though specific terms were not disclosed in the 8-K
- The announcement was made via press release, included as Exhibit 99.1
- The filing was signed by CEO Chun-Hsien Tsai
- Company headquarters: 8880 Rio San Diego Drive, San Diego, CA
This strategic alliance could represent a significant business development for Ainos, potentially impacting its operational capabilities and market position, though investors should refer to the full press release for detailed partnership terms and implications.